Grade 3 or 4 adverse events with FCC (154 courses; N = 43)
| Adverse events* . | Grade 3/4 adverse events . |
|---|---|
| Hematologic, n (% of cycles) | |
| Neutropenia† | 71 (46) |
| Anemia | 13 (8) |
| Thrombocytopenia | 18 (12) |
| Nonhematologic, n (% of cycles) | |
| Hypotension | 1 (0.6) |
| Nausea and vomiting | 15 (10) |
| Diarrhea | 1 (0.6) |
| Bleeding | 1 (0.6) |
| Pulmonary embolism | 1 (0.6) |
| Infections | |
| Major infections, no. of episodes | 12 |
| Pneumonia | 8 |
| Radiologically documented | 6 |
| Nocardia | 1 |
| Scedosporium | 1 |
| Sepsis | 3 |
| Staphylococcus aureus | 2 |
| Pseudomonas aeruginosa | 1 |
| HBV reactivation | 1 |
| Symptomatic CMV reactivation‡ | 8 |
| Adverse events* . | Grade 3/4 adverse events . |
|---|---|
| Hematologic, n (% of cycles) | |
| Neutropenia† | 71 (46) |
| Anemia | 13 (8) |
| Thrombocytopenia | 18 (12) |
| Nonhematologic, n (% of cycles) | |
| Hypotension | 1 (0.6) |
| Nausea and vomiting | 15 (10) |
| Diarrhea | 1 (0.6) |
| Bleeding | 1 (0.6) |
| Pulmonary embolism | 1 (0.6) |
| Infections | |
| Major infections, no. of episodes | 12 |
| Pneumonia | 8 |
| Radiologically documented | 6 |
| Nocardia | 1 |
| Scedosporium | 1 |
| Sepsis | 3 |
| Staphylococcus aureus | 2 |
| Pseudomonas aeruginosa | 1 |
| HBV reactivation | 1 |
| Symptomatic CMV reactivation‡ | 8 |